"Marshall’s rich experience strengthens our board as we move into our next phase of growth," CEO Maggie Nixon said.

Capstan Medical, a developer of robotic-enabled, minimally invasive solutions to address heart valve disease, today announced ...

Sept 23 (Reuters) - Biotech company Arcturus Therapeutics (ARCT.O), opens new tab sued AbbVie (ABBV.N), opens new tab in California federal court on Tuesday for allegedly stealing trade secrets ...

(RTTNews) - AbbVie (ABBV) has completed its acquisition of Capstan Therapeutics, bringing the biotech company under its umbrella. Capstan's lead program, CPTX2309, is a Phase 1 tLNP-based therapy that ...

Acquisition adds a potential first-in-class in vivo targeted lipid nanoparticle (tLNP) anti-CD19 CAR-T therapy candidate for B cell-mediated autoimmune diseases as well as a proprietary tLNP platform ...

NORTH CHICAGO - AbbVie (NYSE:ABBV), a $365 billion market cap biotechnology giant with over $58 billion in annual revenue, announced Tuesday it has completed its acquisition of Capstan Therapeutics, ...

AbbVie will pay US$2.1 billion to acquire Capstan Therapeutics and its in vivo CAR T technology, which uses mRNA-loaded lipid nanoparticles (LNPs) to reprogramme immune cells. Capstan’s lead asset is ...

Capstan Therapeutics — a biotechnology company pioneered by Penn researchers — was acquired by AbbVie in $2.1 billion deal. Capstan, which specializes in CAR-T therapies for autoimmune disorders, ...

One of the perennial challenges of building robots is minimizing the size and weight of drive systems while preserving power. One established way to do this, at least on robots with joints, is to fit ...

AbbVie Inc. (NYSE:ABBV) is one of the most undervalued large cap stocks to buy according to analysts. On June 30, AbbVie announced its intention to acquire Capstan Therapeutics in a deal valued at up ...